Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 6/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 7/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778918 | 0.90 | ROCK1 (0.55) | ROCK1ROCK2TSHR | |
| SCHEMBL4777212 | 0.88 | ROCK1 (0.49) | ROCK1ROCK2RAB9AGSK3BGSK3A | |
| SCHEMBL4725347 | 0.87 | ROCK1 (0.47) | ROCK1ROCK2RAB9AGSK3BGSK3A | |
| SCHEMBL3511578 | 0.84 | ROCK1 (0.52) | ROCK1ROCK2RAB9AGSK3BGSK3A | |
| SCHEMBL3512275 | 0.83 | ROCK1 (0.51) | ROCK1ROCK2RAB9AGSK3BGSK3A | |
| SCHEMBL3508147 | 0.83 | ROCK1 (0.51) | ROCK1ROCK2RAB9AGSK3BGSK3A | |
| SCHEMBL4726379 | 0.81 | TSHR (0.51) | ROCK1ROCK2GSK3BGSK3ATSHR | |
| SCHEMBL353925 | 0.81 | ROCK1 (0.49) | ROCK1ROCK2RAB9AGSK3BGSK3A | |
| SCHEMBL4777130 | 0.80 | ALDH1A1 (0.43) | ROCK1ROCK2GSK3BGSK3ACSNK1D | |
| SCHEMBL4725668 | 0.80 | ROCK1 (0.45) | ROCK1ROCK2GSK3BGSK3ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716320-B2 | Antibacteriall heterocyclic ureas | REPLIDYNE, INC. (US) | 2014-05-06 | — | — | US | claimed |
| US-20080207703-A1 | Antibacterial heterocyclic ureas | REPLIDYNE, INC. (US) | 2008-08-28 | — | — | US | claimed |
| US-8716320-B2 | Antibacteriall heterocyclic ureas | REPLIDYNE, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20080207703-A1 | Antibacterial heterocyclic ureas | REPLIDYNE, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008011191-A1 | ANTIBACTERIAL HETEROCYCLIC UREAS | REPLIDYNE, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207703-A1 | Antibacterial heterocyclic ureas | UMPS, UROD, UGP2 | ROCK1 4331/4885ROCK2 4405/4885RAB9A 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.